In last trading session, Taysha Gene Therapies Inc (NASDAQ:TSHA) saw 2.93 million shares changing hands with its beta currently measuring 0.93. Company’s recent per share price level of $2.37 trading at $0.03 or 1.28% at ring of the bell on the day assigns it a market valuation of $485.98M. That closing price of TSHA’s stock is at a discount of -82.28% from its 52-week high price of $4.32 and is indicating a premium of 55.7% from its 52-week low price of $1.05. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 4.49 million shares which gives us an average trading volume of 2.44 million if we extend that period to 3-months.
For Taysha Gene Therapies Inc (TSHA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.09. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Taysha Gene Therapies Inc (NASDAQ:TSHA) trade information
Upright in the green during last session for gaining 1.28%, in the last five days TSHA remained trading in the green while hitting it’s week-highest on Wednesday, 05/14/25 when the stock touched $2.37 price level, adding 3.27% to its value on the day. Taysha Gene Therapies Inc’s shares saw a change of 36.99% in year-to-date performance and have moved 24.74% in past 5-day. Taysha Gene Therapies Inc (NASDAQ:TSHA) showed a performance of 85.16% in past 30-days. Number of shares sold short was 26.06 million shares which calculate 10.16 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 8.5 to the stock, which implies a rise of 72.12% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 44. It follows that stock’s current price would drop -110.97% in reaching the projected high whereas dropping to the targeted low would mean a loss of -110.97% for stock’s current value.
Taysha Gene Therapies Inc (TSHA) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -63.99% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 3.49% while estimates for its earnings growth in next 5 years are of 8.17%.
Taysha Gene Therapies Inc (NASDAQ:TSHA)’s Major holders
Insiders are in possession of 17.95% of company’s total shares while institution are holding 81.09 percent of that, with stock having share float percentage of 98.83%. Investors also watch the number of corporate investors in a company very closely, which is 81.09% institutions for Taysha Gene Therapies Inc that are currently holding shares of the company. FMR LLC is the top institutional holder at TSHA for having 21.21 million shares of worth $47.51 million. And as of 2024-06-30, it was holding 9.1103 of the company’s outstanding shares.
The second largest institutional holder is RTW INVESTMENTS, LP, which was holding about 18.8 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.075 of outstanding shares, having a total worth of $42.11 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 4.85 shares of worth $11.49 million or 2.36% of the total outstanding shares. The later fund manager was in possession of 4.58 shares on Mar 31, 2025 , making its stake of worth around $10.86 million in the company or a holder of 2.23% of company’s stock.
